- •November 16, 2002
- •February 14, 2003
- •February 21
- •February 28
- •March 7
- •March 10
- •March 12
- •March 14
- •March 15
- •March 17
- •March 19
- •March 21
- •March 24
- •March 26
- •March 28
- •March 30
- •March 31
- •April 2
- •April 2
- •April 8-10
- •April 12
- •April 16
- •April 20
- •April 20
- •April 23
- •April 25
- •April 27
- •April 29
- •June 6
- •June 13
- •June 17
- •June 21
- •June 23
- •June 24
- •July 2
- •July 5
- •August 14
- •September 8
- •September 24
- •References
- •Virology
- •Discovery of the SARS Virus
- •Initial Research
- •The Breakthrough
- •Coronaviridae
- •SARS Co-V
- •Genome Sequence
- •Morphology
- •Organization
- •Detection
- •Stability and Resistance
- •Natural Host
- •Antiviral Agents and Vaccines
- •Antiviral Drugs
- •Vaccines
- •Outlook
- •References
- •Routes of Transmission
- •Factors Influencing Transmission
- •Patient Factors in Transmission
- •Asymptomatic Patients
- •Symptomatic Patients
- •Superspreaders
- •The Unsuspected Patients
- •High-Risk Activities
- •Transmission during Quarantine
- •Transmission after Recovery
- •Animal Reservoirs
- •Conclusion
- •References
- •Introduction
- •Modeling the Epidemic
- •Starting Point
- •Global Spread
- •Hong Kong
- •Vietnam
- •Toronto
- •Singapore, February 2003
- •China
- •Taiwan
- •Other Countries
- •Eradication
- •Outlook
- •References
- •Introduction
- •International Coordination
- •Advice to travelers
- •Management of SARS in the post-outbreak period
- •National Measures
- •Legislation
- •Extended Case Definition
- •Quarantine
- •Reduce travel between districts
- •Quarantine after Discharge
- •Infection Control in Healthcare Settings
- •General Measures
- •Protective Measures
- •Hand washing
- •Gloves
- •Face Masks
- •Additional protection
- •Getting undressed
- •Special Settings
- •Intensive Care Units
- •Intubating a SARS Patient
- •Anesthesia
- •Triage
- •Internet Sources
- •Additional information
- •Infection Control in Households
- •Possible Transmission from Animals
- •After the Outbreak
- •Conclusion
- •References
- •Case Definition
- •WHO Case Definition
- •Suspect case
- •Probable case
- •Exclusion criteria
- •Reclassification of cases
- •CDC Case Definition
- •Diagnostic Tests
- •Introduction
- •Laboratory tests
- •Molecular tests
- •Virus isolation
- •Antibody detection
- •Interpretation
- •Limitations
- •Biosafety considerations
- •Outlook
- •Table, Figures
- •References
- •Clinical Presentation and Diagnosis
- •Clinical Presentation
- •Hematological Manifestations
- •Atypical Presentation
- •Chest Radiographic Abnormalities
- •Chest Radiographs
- •CT Scans
- •Diagnosis
- •Clinical Course
- •Viral Load and Immunopathological Damage
- •Histopathology
- •Lung Biopsy
- •Postmortem Findings
- •Discharge and Follow-up
- •Psychosocial Issues
- •References
- •Appendix: Guidelines
- •WHO: Management of Severe Acute Respiratory Syndrome (SARS)
- •Management of Suspect and Probable SARS Cases
- •Definition of a SARS Contact
- •Management of Contacts of Probable SARS Cases
- •Management of Contacts of Suspect SARS Cases
- •SARS Treatment
- •Antibiotic therapy
- •Antiviral therapy
- •Ribavirin
- •Neuraminidase inhibitor
- •Protease inhibitor
- •Human interferons
- •Human immunoglobulins
- •Alternative medicine
- •Immunomodulatory therapy
- •Corticosteroids
- •Other immunomodulators
- •Assisted ventilation
- •Non-invasive ventilation
- •Invasive mechanical ventilation
- •Clinical outcomes
- •Outlook
- •Appendix 1
- •A standardized treatment protocol for adult SARS in Hong Kong
- •Appendix 2
- •A treatment regimen for SARS in Guangzhou, China
- •References
- •Pediatric SARS
- •Clinical Manifestation
- •Radiologic Features
- •Treatment
- •Clinical Course
- •References
Discharge and Follow-up 137
supports the contention that cytokine dysregulation may account, at least partly, for the severity of the clinical disease (Nicholls).
Examination of the liver revealed microvesicular fatty change, focal hemorrhages, and hepatocyte necrosis with scattered acidophilic bodies. The spleen showed large areas of probable ischemic necrosis and some atypical lymphocytes in the periarteriolar sheaths (Poutanen).
In one series, autopsy of hemato-lymphoid organs from four patients showed neither enlarged lymph nodes in the peripheral soft tissues or other body parts, nor reactive lymphoid hyperplasia or T zone reaction. The splenic white pulps appeared atrophic with lymphoid depletion, and the red pulp was congested. Bone marrow appeared active with the presence of three lineages. No features of hypoplastic marrow or reactive hemophagocytic syndrome were noted (Wong R).
Discharge and Follow-up
The duration of shedding of the SARS virus from respiratory secretions of SARS patients appears to be variable. Some animals can shed infectious coronavirus persistently from the enteric tract for weeks or months without signs of disease, transmitting the infectious virus to neonates and other susceptible animals (Holmes). Studies are being done to learn whether the SARS virus is shed persistently from the respiratory and/or enteric tracts of some humans without signs of disease (Holmes). In the meantime, all SARS patients should limit interactions outside the home and should not go to work, school, out- of-home childcare, or other public areas until 10 to 14 days after the fever and respiratory symptoms have resolved. During this time, the infection control precautions for SARS patients should be followed. In a small study of 14 patients, none reported secondary cases in their household following their discharge home (Avendano).
At a follow-up visit one week after discharge, all 14 patients in one series still felt weak and complained of dyspnea on exertion. They all reported significant weight loss during their acute illness (mean 7 kg). Two patients had had a low grade fever (up to 37.5°C) for 2–3 days following discharge. Only 2 patients had persistence of a slight dry cough. The chest radiograph was clear for 7 patients and, although
Kamps and Hoffmann (eds.)